Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024
Narjust Florez(Harvard University), Edward S. Kim(The University of Texas MD Anderson Cancer Center), Roy S. Herbst(Smilow Cancer Hospital), Misty Dawn Shields(Indiana University Health), Aakash Desai(Jacksonville College), Joshua K. Sabari(NYU Langone Health), Anjali Sibley(Center for Disease Analysis), Erminia Massarelli(The University of Texas MD Anderson Cancer Center), Lyudmila Bazhenova(University of California San Diego), Hatim Husain(University of California, San Diego), Heather A. Wakelee(Palo Alto Institute), David R. Gandara(University of California, Davis), Martin Dietrich(Cancer Care Centers of Brevard), Percy Lee(City Of Hope National Medical Center), Christine M. Bestvina(University of Chicago Medicine Comprehensive Cancer Center), Jacob Sands(Harvard University), Solange Peters(University Hospital of Lausanne), Sandip Pravin Patel(University of California San Diego), Fred R. Hirsch(Tisch Hospital), Elaine Shum(NYU Langone’s Laura and Isaac Perlmutter Cancer Center), Hari B. Keshava(University of California, Irvine), Kristin Higgins(Emory University), Balázs Halmos(Montefiore Medical Center), Jonathan W. Riess(University of California Davis Medical Center), Leah M. Backhus(Stanford University), Ana I. Velázquez(University of California, San Francisco), Ravi Salgia(City Of Hope National Medical Center), Triparna Sen(Icahn School of Medicine at Mount Sinai), Julia Rotow(University of California, San Francisco)
Cited by 3
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k